Emerging azole antifungals
The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Systemic and superficial fungal infections have progressively emerged over the past few decades as an increasing cause of human disease, especially in the immunocompromised host. Control of fungal disease has proved difficult because few risk factors are potentially preventable; the population at highest risk for fungal disease, the immunocompromised patient, has been steadily increasing. There is a clear need for additional safe and effective therapeutic agents for the treatment of systemic fungal disease. A new generation of triazoles that includes voriconazole, posaconazole, ravuconazole and albaconazole has emerged and are presently in different phases of clinical investigation. These new triazoles have demonstrated a broad spectrum of activity, in particular against fungal pathogens previously resistant to previously available antifungals. This review highlights the emerging azole antifungals, both those available and in clinical development, and discusses their prospects for the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
Herbrecht, R., Denning, D. W., Patterson, T. F., Bennett, J. E., Greene, R. E., Oestmann, J.-W., Kern, W. V., Marr, K. A., Ribaud, P., Lortholary, O., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020191 · Cited by 3,304
Attributable Mortality of Nosocomial Candidemia, Revisited
Gudlaugsson, O., Gillespie, S., Lee, K., Berg, J. V., Hu, J., Messer, S., Herwaldt, L., Pfaller, M., & Diekema, D. (2003) · Clinical Infectious Diseases · doi:10.1086/378745 · Cited by 1,140
Current and emerging azole antifungal agents
Sheehan, D. J., Hitchcock, C. A., & Sibley, C. M. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.1.40 · Cited by 1,137
Rex, J. H., Bennett, J. E., Sugar, A. M., Pappas, P. G., van der Horst, C. M., Edwards, J. E., Washburn, R. G., Scheld, W. M., Karchmer, A. W., Dine, A. P., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411173312001 · Cited by 1,039 · cited 1×
“Despite appropriate antifungal therapy, persistent candidemia is reported in 10 – 15% of cases [18].”
BackgroundWalsh, T. J., Pappas, P., Winston, D. J., Lazarus, H. M., Petersen, F., Raffalli, J., Yanovich, S., Stiff, P., Greenberg, R., Donowitz, G., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejm200201243460403 · Cited by 979 · cited 1×
“Although the study demonstrated that voriconazole was a suitable alternative to liposomal amphotericin B for the treatment of neutropenia and persistent fever, the primary end point of non-inferiority was not met [74].”
ResultGrant, S. M., & Clissold, S. P. (1990) · Drugs · doi:10.2165/00003495-199039060-00006 · Cited by 661
Trends in Mortality Due to Invasive Mycotic Diseases in the United States, 1980–1997
McNeil, M. M., Nash, S. L., Hajjeh, R. A., Phelan, M. A., Conn, L. A., Plikaytis, B. D., & Warnock, D. W. (2001) · Clinical Infectious Diseases · doi:10.1086/322606 · Cited by 657
Trends in Infectious Diseases Mortality in the United States
Pinner, R. W. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03530270029027 · Cited by 487 · cited 1×
“Mycotic diseaserelated fatalities have increased more than threefold since 1980 [3].”
BackgroundPfaller, M. A., Jones, R. N., Doern, G. V., Sader, H. S., Messer, S. A., Houston, A., Coffman, S., Hollis, R. J., & The SENTRY Participant Group (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.3.747-751.2000 · Cited by 378
The direct cost and incidence of systemic fungal infections
Wilson, L. S., Reyes, C. M., Stolpman, M., Speckman, J., Allen, K., & Beney, J. (2002) · Value in Health · doi:10.1046/j.1524-4733.2002.51108.x · Cited by 374
Cited by
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174
Pfaller, M. A., Diekema, D. J., Gibbs, D. L., Newell, V. A., Ellis, D., Tullio, V., Rodloff, A., Fu, W., & Ling, T. A. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.02117-09 · Cited by 718
“Given the ubiquitous use of azoles in prophylaxis and empirical and directed therapies (4, 43, 65, 66), it is important to know the activities of the systemically active agents, such as fluconazole and voriconazole, against these organisms (65, 66).”
BackgroundPfaller, M. A., Diekema, D. J., Gibbs, D. L., Newell, V. A., Bijie, H., Dzierzanowska, D., Klimko, N. N., Letscher-Bru, V., Lisalova, M., Muehlethaler, K., et al. (2009) · Journal of Clinical Microbiology · doi:10.1128/jcm.01747-08 · Cited by 370
Synthesis and antifungal activity of 1,2,3-triazole containing fluconazole analogues
Aher, N. G., Pore, V. S., Mishra, N. N., Kumar, A., Shukla, P. K., Sharma, A., & Bhat, M. K. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.12.026 · Cited by 328
Posaconazole: a broad-spectrum triazole antifungal
Torres, H. A., Hachem, R. Y., Chemaly, R. F., Kontoyiannis, D. P., & Raad, I. I. (2005) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(05)70297-8 · Cited by 285
Metadata
- Authors
- Chen, A., & Sobel, J. D.
- Venue
- Expert Opinion on Emerging Drugs
- Publisher
- Informa Healthcare
- Published
- 2005-02
- Volume
- 10
- Issue
- 1
- Pages
- 21-33
- ISSN
- 1472-8214 (ISSN-L)
- 1744-7623
- OpenAlex
- W2136619689
- Cited by
- 59
- References
- 16
- FWCI
- 3.80
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Emerging azole antifungals. https://app.cochat.ai/papers/10.1517/14728214.10.1.21
- The paper
- Chen, A., & Sobel, J. D. (2005). Emerging azole antifungals. Expert Opinion on Emerging Drugs. https://doi.org/10.1517/14728214.10.1.21
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.